Zylox-Tonbridge Medical Technology Co., Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100004JD2
HKD
23.40
0.26 (1.12%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 1.12%

  • Poor long term growth as Operating profit has grown by an annual rate 34.05% of over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -160.57
2

With ROE of 5.66%, it has a Expensive valuation with a 2.15 Price to Book Value

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

HKD 7,770 Million ()

stock-summary
P/E

38.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.49

stock-summary
Return on Equity

5.62%

stock-summary
Price to Book

2.25

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-11.7%
0%
-11.7%
6 Months
4.28%
0%
4.28%
1 Year
86.31%
0%
86.31%
2 Years
130.31%
0%
130.31%
3 Years
60.27%
0%
60.27%
4 Years
39.95%
0%
39.95%
5 Years
0%
0%
0.0%

Zylox-Tonbridge Medical Technology Co., Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
45.73%
EBIT Growth (5y)
34.05%
EBIT to Interest (avg)
-160.57
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.38
Sales to Capital Employed (avg)
0.15
Tax Ratio
0
Dividend Payout Ratio
32.42%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0.85%
ROE (avg)
1.12%

Valuation key factors

Factor
Value
P/E Ratio
38
Industry P/E
Price to Book Value
2.15
EV to EBIT
49.21
EV to EBITDA
41.67
EV to Capital Employed
3.23
EV to Sales
5.92
PEG Ratio
0.12
Dividend Yield
NA
ROCE (Latest)
6.56%
ROE (Latest)
5.66%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Zylox-Tonbridge Medical Technology Co., Ltd."
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is 50.12% vs 81.20% in Dec 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is 34.14% vs 45.12% in Dec 2022",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "583.20",
          "val2": "388.50",
          "chgp": "50.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-170.10",
          "val2": "-238.10",
          "chgp": "28.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.40",
          "val2": "0.80",
          "chgp": "75.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "5.60",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-87.00",
          "val2": "-132.10",
          "chgp": "34.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-291.70%",
          "val2": "-691.50%",
          "chgp": "39.98%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Dec'23stock-summary

Dec'23
Dec'22
Change(%)
Net Sales
583.20
388.50
50.12%
Operating Profit (PBDIT) excl Other Income
-170.10
-238.10
28.56%
Interest
1.40
0.80
75.00%
Exceptional Items
0.00
5.60
-100.00%
Consolidate Net Profit
-87.00
-132.10
34.14%
Operating Profit Margin (Excl OI)
-291.70%
-691.50%
39.98%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2023 is 50.12% vs 81.20% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is 34.14% vs 45.12% in Dec 2022

stock-summaryCompany CV
About Zylox-Tonbridge Medical Technology Co., Ltd. stock-summary
stock-summary
Zylox-Tonbridge Medical Technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available